PPN maintains the most up to date clinical guidelines for PANS and PANDAS. Guidelines will always be based on published information and further refined and explained by the Diagnostics & Therapeutics Committee.
PPN Treatment Options aim to provide the breadth of potential therapies for PANDAS and PANS, updated for the latest research and experience of clinicians. There are a variety of treatment options available.
“Seeing Your First Child with PANDAS/PANS” is a medical guide consisting of: overview and current theories, PANS diagnostic criteria, PANS workup recommendations, and setting medical and family expectations.
PANS/PANDAS RESEARCH UPDATES
PPN’s comprehensive collection of published works includes the original published studies from the NIMH team that first reported on the PANDAS condition as well as the primary additional studies that followed. The library consists of a synopsis and critique of each study.
NEW RESEARCH: PANDAS IVIG STUDY PUBLISHED
New IVIG study shows 60% mean reduction in symptoms for PANDAS patients.
A new paper submitted to the Journal of the American Academy of Child & Adolescent Psychiatry describes the outcome of the NIMH double-blind placebo controlled study of IVIG for treatment of symptoms in children who met the criteria of PANDAS.
NEW RESEARCH: THE EFFECT OF NSAIDs ON PANS SYMPTOMS
This observational study describes the course of neuropsychiatric symptoms in patients diagnosed with PANS and PANDAS after introduction or removal of nonsteroidal anti-inflammatory drugs (NSAIDs). Improvement in neuropsychiatric symptoms was evident in roughly one-third of NSAID treatment trials.
TREATMENT GUIDELINES PUBLISHED
The PANS/PANDAS Research Consortium has published new treatment guidelines in the Journal of Child and Adolescent Psychopharmacology. The 3 articles include recommendations on:
► Antimicrobials and secondary prophylaxis
► Immunomodulating therapies based on symptom severity
► Management of symptoms while simultaneously addressing the instigating processes (which includes infections and inflammatory disease)
PPN is an organization that is dedicated to helping medical professionals better understand PANDAS and PANS through real-time information and networking. PPN Guidelines for Diagnostics and Therapeutics are developed by PPN committees and special advisors from the top academic medical institutions in the United States, including Harvard, Yale, Stanford, Columbia, Georgetown, NIH, and NIMH. Members of this elite group have worked with, treated, or studied the patients or aspects of the disorder. Because PANDAS and PANS are interdisciplinary disorders, all the relevant disciplines are represented on the PPN committees and the special advisory council.
The PPN Registry will be the primary PANDAS and PANS registry in the country. The HIPAA compliant, on-line registry includes parent and physician data on single patients thereby producing two data sets that can be used for research and diagnostic & treatment refinements.
MEDICAL PROFESSIONALS: BECOME A MEMBER OF PPN
It’s free to become a member of the PPN. Benefits include:
► Communicate and ask questions to your peers
► Receive email alerts on new research, guidelines, and treatment protocols
► Option to be recognized as a practitioner who works with PANS/PANDAS patients
CHANGE THE COURSE OF MENTAL ILLNESS WITHIN A GENERATION
PPN’s goal is to help medical professionals understand, diagnose and treat PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) and PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) by providing to them quality research, diagnostic and treatment tools. Your donation dollars will not only help maintain PPN’s tools, but will help further prove that the immune system can cause such psychological distress.